Skip to content

Monopar Therapeutics MNPR Operating Lease ROU Assets

Operating Lease ROU Assets at other companies

Prime Medicine logo
Prime MedicinePRME
$123.33M-1.6%
Wave Life Sciences logo
Wave Life SciencesWVE
$10.99M-33.7%
Perspective Therapeutics logo
Perspective TherapeuticsCATX
$2.44M+22.6%
Amylyx Pharmaceuticals, Inc. logo
Amylyx Pharmaceuticals, Inc.AMLX
$4.88M+289%
ArriVent BioPharma, Inc. logo
ArriVent BioPharma, Inc.AVBP
$370K+208%
Precigen logo
PrecigenPGEN
11.4%-0.1pp

Other financials

Income statement

See full
Revenue-
Operating income-$5.2M-62.2%
Net income-$3.9M-48.3%
EPS (diluted)-$0.19

Balance sheet

See full
Cash & equivalents$52.5M+32.3%
Total debt$230.4K+2,692%
Total equity$135.4M+153%
Total assets$138.0M+150%

Cash flow

See full
Operating cash flow-$3.5M+38.7%

Valuation

See full
Market cap$587.04M+192%
Enterprise value$534.72M+232%

Returns & leverage

See full
Return on equity-15.9%-6.6pp
Debt / equity0.0×
Current ratio56×

Where this comes from

Reported directly by Monopar Therapeutics in its filing.

Tagged under the XBRL concept us-gaap:OperatingLeaseRightOfUseAsset.

The official record: Monopar Therapeutics’s 10-Q, filed May 14, 2026, on SEC EDGAR. View the filing →

Ask your AI about Monopar Therapeutics's operating lease rou assets.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Monopar Therapeutics's operating lease ROU assets?
Monopar Therapeutics (MNPR) reported operating lease ROU assets of $239.88K in Q1 2026.
How has Monopar Therapeutics's operating lease ROU assets changed year-over-year?
Monopar Therapeutics's operating lease ROU assets increased by 2535.5% year-over-year, from $9.1K to $239.88K.
What does operating lease ROU assets mean?
Right-of-use assets representing the lessee's right to use leased property over the lease term under ASC 842 operating lease classification.